- 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class…
After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p <…
In a release issued under the same headline on July 12, 2024 by Onco360 Oncology Pharmacy, please note the change…
ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients…
FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical…
VANCOUVER, BC / ACCESSWIRE / July 17, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to…
CHENGDU, China, July 16, 2024 /PRNewswire/ -- "Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery" webinar will be…
TEL AVIV, Israel, July 16, 2024 /PRNewswire/ -- A patient in Cincinnati has become the first in the United States…
Non-Ionic EVQ-218 Demonstrates Success in Combating Leading Pathogens Without Triggering Antimicrobial Resistance (AMR) SALT LAKE CITY, July 16, 2024 /PRNewswire/…
SAN ANTONIO, July 16, 2024 /PRNewswire/ -- RealTime eClinical Solutions, a leading provider of innovative clinical trial management technology, is proud…